Op/Ed: Why Rare Disease Brands Are Losing Patients at Critical Moments

Picture the moment a neurologist finally puts a name to what has been, for a patient and their family, years of unexplained symptoms. The diagnosis is rare. The treatment exists. The physician is ready to act. And then, the access workflow fails them.

Not because the drug isn’t covered. Not because the HCP isn’t motivated. But because no one equipped that physician for what comes next: the referral handoff, the prior authorization initiation, the hub enrollment process. Each of those moments is a decision point. Each is an opportunity for the access pathway to stall. And in rare disease, a stall rarely self-corrects.

This failure is largely preventable. It typically starts with a gap in how most specialty pharma brands approach HCP journey mapping.

What Are the Missing Gaps in Traditional Pharma Journey Mapping?

Most HCP journey maps are built for commercial outcomes. They chart the arc from awareness through consideration to prescribing intent, with message strategies designed to move physicians along that funnel. That architecture made sense when the primary commercial problem was getting HCPs to choose your drug over a competitor’s.

In specialty and rare disease, prescribing decisions are rarely the hard part. The hard part is what happens after. Referral logistics. Benefits verification. Prior authorization. Hub program enrollment. Patient assistance navigation. These are the moments where patients lose access, and they are almost universally absent from the journey maps that brand and commercial teams build.

The result is a messaging strategy that ends where the access challenge begins.

Why Is the Access Pathway More Difficult for Rare Diseases?

In primary care, access friction is frustrating but often recoverable. A physician who encounters a prior authorization barrier will navigate it or try again next month. The volume of patients and the frequency of prescribing create a kind of muscle memory around access processes.

In rare disease, that muscle memory doesn’t exist. A specialist may diagnose two or three patients with a given condition per year. They navigate the access pathway infrequently, which means the process never becomes routine. Each handoff moment, referral, PA initiation, hub enrollment, is effectively new or forgotten terrain.

When those handoff moments aren’t supported with the right information at the right time, the pathway stops. Patients disengage. Caregivers lose confidence. Physicians, frustrated by administrative complexity, redirect their attention elsewhere. The cost of friction in rare disease isn’t a delayed refill. It’s a patient who never starts therapy.

How Can Pharma optimize Journey Mapping for Better Patient Access?

The solution isn’t a new journey map. It’s a re-anchoring of message strategy to the access pathway rather than the commercial funnel alone. At each handoff moment, ask what the HCP needs to know, understand, and do to keep the patient moving forward.

That question reframes the entire content and channel strategy. A physician initiating a prior authorization doesn’t need another efficacy message, they’ve already prescribed. They need documentation guidance, clear clinical criteria language, and a direct line to field reimbursement support. An HCP navigating hub enrollment for the first time needs concise orientation to the process, not a reminder of why the drug works.

When message strategy is mapped to access pathway stages rather than commercial stages, three things happen: content becomes more useful to HCPs, channel deployment becomes more precise, and the operational teams; market access, hub services, field reimbursement, finally have a shared framework for coordinating around the patient pathway.

What Does This Look Like in Practice?

Working with a rare disease brand navigating a complex specialty access environment, our team identified that the highest point of patient pathway abandonment wasn’t at diagnosis or even at prescribing, it was at hub enrollment. HCPs were completing the prescribing decision but failing to submit enrollment documentation correctly, often because they were unclear on what was required or didn’t know where to direct their staff.

By mapping message content specifically to the enrollment handoff moment, HCPs and their office staff have the information they need to keep the process moving. Outreach isn’t a campaign. It is a content and channel alignment, driven by understanding where the handoff breaks down.

The Question Your Journey Map Can’t Answer

The question for most rare disease brands isn’t whether they have a journey map. They almost certainly do. The question is whether that journey map has ever been directed as a hub workflow, a PA appeal letter, or a reimbursement coordinator’s daily reality.

If your message architecture ends at “prescribing intent,” you’ve mapped the easy part of the journey. The hard part, where patients gain or lose access, starts at the handoff. Right now, most brands aren’t mapping that critical message.

A few questions worth exploring with your own commercial and market access teams:

• Does your current message strategy distinguish between what an HCP needs to hear at diagnosis versus at PA initiation versus at hub enrollment?
• Are your market access team and your commercial team working from the same journey framework or two separate ones that never quite meet?
• Can you identify, by name, the three handoff moments in your access pathway where patient dropout is most likely and the content that exists to support HCPs through each one?

If those questions surface gaps, they’re not a strategic failure, they’re an operational one. And operational failures, unlike strategic ones, can be fixed. The map just needs to go further.

Anthony Bianciella is the vice president of Marketing Operations and Learning Services at Conexus Solutions.